Prevalence and Clinical Significance of FLT3 Mutation Status in Acute Myeloid Leukemia Patients: A Multicenter Study

详细信息    查看全文

• 作者：Jorge Cuervo-Sierra^a ; José ; Carlos Jaime-Pé ; rez^a ; ^{carjaime@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Ramó ; n A. Martí ; nez-Herná ; ndez^a ; Ricardo D. Garcí ; a-Sepú ; lveda^a ; Mó ; nica Sá ; nchez-Cá ; rdenas^a ; David Gó ; mez-Almaguer^a ; Rocí ; o Ortí ; z-Ló ; pez^b ; Cé ; sar D. Villarreal-Villarreal^a ; Guillermo J. Ruiz-Arguelles^c ; Guillermo Ruiz-Delgado^c ; Julia Lutz-Presno^c ; Javier Garcé ; s-Eisele^c ; ^d ; Gregorio Ignacio-Ibarra^e ; ^f ; Gabriel Muciñ ; o-Herná ; ndez^e ; ^g ; Rosa M. Arana-Trejo^e ; ^g ; Angé ; lica M. Jimé ; nez-Mejia^h ; Gonzalo Vá ; squez-Palacio^h
• 关键词：Acute myeloid leukemia ; AML ; FLT3 ; Latin America
• 刊名：Archives of Medical Research
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：47
• 期：3
• 页码：172-179
• 全文大小：358 K

文摘

FLT3-ITD mutations in acute myeloid leukemia (AML) are associated with a poor prognosis. In Latin America, little epidemiological data exist about these mutations and their influence on clinical evolution and prognosis. Standardization and well-established clinical correlation make FLT3 mutational analysis by molecular methods an invaluable tool to decide among treatment options and to determine AML prognosis.

Methods

We assessed the prevalence of FLT3-ITD mutations in 138 patients with AML at four hematology referral centers from Mexico and Colombia. Molecular methods based on polymerase chain reaction (PCR) were employed for determining FLT3-ITD status.

Results

Mutations were present in 28 patients indicating a prevalence of 20.28%. Median age was 47 years (5–96). The FLT3 mutation positive group was older, had higher WBC and hemoglobin values and lower platelet counts but without statistical significance. A not previously described mutation in the FLT3 gene was found in one patient involving a nucleotide exchange of timine for cytosine at the 66608 position. A high mortality was found in the FLT3-mutated group, 67.8 vs. 42.72% in the non-mutated group and median survival was 4.9 months vs. 20.4 months, p = 0.009. A mutated FLT3 did not confer poor prognosis to those with M3 AML. The mutated FLT3 population had poor overall survival (OS) despite hematoprogenitor stem cell transplantation (HSCT).

Conclusion

Prevalence of FLT3-ITD mutation in AML was present in a proportion comparable to other populations and, when present, was associated with a very poor prognosis.